Targeted alpha PSMA-based therapy of metastatic castrate-resistant prostate-cancer patients (mCRPC): prediction dosimetry

Category Primary study
JournalPhysica Medica
Year 2021
This article has no abstract
Epistemonikos ID: bf5a36ecb950059adcdee13bcdb3ab40c8e03fce
First added on: Feb 13, 2025